Inflammatory bowel disease in chronic granulomatous disease: An emerging problem over a twenty years' experience

Pediatric Allergy and Immunology

Volumn 28, Issue 8, 2017, Pages 801-809

  Angelino, Giulia ^a,b   De Angelis, Paola ^a   Faraci, Simona ^a   Rea, Francesca ^a   Romeo, Erminia Francesca ^a   Torroni, Filippo ^a   Tambucci, Renato ^a,c   Claps, Alessia ^b   Francalanci, Paola ^a   Chiriaco, Maria ^b   Di Matteo, Gigliola ^b   Cancrini, Caterina ^b   Palma, Paolo ^b   D'Argenio, Patrizia ^b   Dall'Oglio, Luigi ^a   Rossi, Paolo ^b   Finocchi, Andrea ^b  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

^c UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

digestive endoscopy; granulomatous colitis; primary immunodeficiency; very early onset IBD (VEO IBD)

Indexed keywords

ALBUMIN; AZATHIOPRINE; C REACTIVE PROTEIN; CALGRANULIN; CIPROFLOXACIN; MESALAZINE; METRONIDAZOLE; NEUTROPHIL CYTOPLASMIC ANTIBODY; STEROID; ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ADOLESCENT; ADULT; AGING; ARTICLE; BLOOD TRANSFUSION; CHILD; CHRONIC GRANULOMATOUS DISEASE; CLINICAL ARTICLE; CLINICAL FEATURE; COLITIS; COMORBIDITY; DIARRHEA; EOSINOPHILIA; FEMALE; FOLLOW UP; GASTROINTESTINAL ENDOSCOPY; GRANULOMA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INFECTION; INFLAMMATORY BOWEL DISEASE; IRON DEFICIENCY ANEMIA; ITALY; LYMPHOCYTOPENIA; MACROPHAGE; MAINTENANCE THERAPY; MALE; NEUTROPHILIA; PERIANAL ABSCESS; PNEUMONIA; PRESCHOOL CHILD; PRIORITY JOURNAL; RECTUM HEMORRHAGE; REMISSION; RETROSPECTIVE STUDY; SCHOOL CHILD; SEPSIS; SYMPTOM; TERTIARY CARE CENTER; TOTAL PARENTERAL NUTRITION; TREATMENT OUTCOME; YOUNG ADULT; COMPLICATION; RECURRENT DISEASE;

ADOLESCENT; ADULT; ANTI-INFLAMMATORY AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; RECURRENCE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85034024450     PISSN: 09056157     EISSN: 13993038     Source Type: Journal    
DOI: 10.1111/pai.12814     Document Type: Article

References (31)

1. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM. Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore). 2000;79:170-200.
2. Roos D, de Boer M. Molecular diagnosis of chronic granulomatous disease. Clin Exp Immunol. 2014;175:139-149.
3. Assari T. Chronic granulomatous disease; fundamental stages in our understanding of CGD. Med Immunol. 2006;5:4.
4. Khangura SK, Kamal N, Ho N, et al. Gastrointestinal features of chronic granulomatous disease found during endoscopy. Clin Gastroenterol Hepatol. 2016;14:e5.
5. Uhlig HH, Schwerd T, Koletzko S, et al. The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology. 2014;147:e3.
6. Kelsen JR, Baldassano RN, Artis D, Sonnenberg GF. Maintaining intestinal health: the genetics and immunology of very early onset inflammatory bowel disease. Cell Mol Gastroenterol Hepatol. 2015;1:462-476.
7. Dhillon SS, Fattouh R, Elkadri A, et al. Variants in nicotinamide adenine dinucleotide phosphate oxidase complex components determine susceptibility to very early onset inflammatory bowel disease. Gastroenterology. 2014;147:e2.
8. Huang C, De Ravin SS, Paul AR, et al. Genetic risk for inflammatory bowel disease Is a determinant of crohn's disease development in chronic granulomatous disease. Inflamm Bowel Dis. 2016;22:2794-2801.
9. Seger RA, Gungor T, Belohradsky BH, et al. Treatment of chronic granulomatous disease with myeloablative conditioning and an unmodified hemopoietic allograft: a survey of the European experience, 1985-2000. Blood. 2002;100:4344-4350.
10. Güngör T, Teira P, Slatter M, et al. Inborn errors working party of the European society for blood and marrow transplantation. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study. Lancet. 2014;383:436-448.
11. Magnani A, Brosselin P, Beauté J, et al. Inflammatory manifestations in a single-center cohort of patients with chronic granulomatous disease. J Allergy Clin Immunol. 2014;134:e8.
12. Timmer A, Behrens R, Buderus S, et al. Childhood onset inflammatory bowel disease: predictors of delayed diagnosis from the CEDATA German-language pediatric inflammatory bowel disease registry. J Pediatr. 2011;158:e2.
13. Kawai T, Arai K, Harayama S, et al. Severe and rapid progression in very early-onset chronic granulomatous disease-associated colitis. J Clin Immunol. 2015;35:583-588.
14. Levine A, Koletzko S, Turner D, et al. ESPGHAN revised porto criteria for the diagnosis of inflammatory bowel disease in children and adolescents. J Pediatr Gastroenterol Nutr. 2014;58:795-806.
15. Yu JE, De Ravin SS, Uzel G, et al. High levels of crohn's disease-associated anti-microbial antibodies are present and independent of colitis in chronic granulomatous disease. Clin Immunol. 2011;138:14-22.
16. Broides A, Sagi O, Pinsk V, Levy J, Yerushalmi B. Subclinical intestinal inflammation in chronic granulomatous disease patients. Immunol Res. 2016;64:155-159.
17. Alimchandani M, Lai JP, Aung PP, et al. Gastrointestinal histopathology in chronic granulomatous disease: a study of 87 patients. Am J Surg Pathol. 2013;37:1365-1372.
18. Schäppi MG, Klein NJ, Lindley KJ, et al. The nature of colitis in chronic granulomatous disease. J Pediatr Gastroenterol Nutr. 2003;36:623-631.
19. Hauck F, Koletzko S, Walz C, et al. Diagnostic and treatment options for severe IBD in female X-CGD carriers with non-random X-inactivation. J Crohns Colitis. 2016;10:112-115.
20. Turner D, Levine A, Escher JC, et al. Management of pediatric ulcerative colitis: joint ECCO and ESPGHAN evidence-based consensus guidelines. J Pediatr Gastroenterol Nutr. 2012;55:340-361.
21. Ruemmele FM, Veres G, Kolho KL, et al. Consensus guidelines of ECCO/ESPGHAN on the medical management of pediatric Crohn's disease. J Crohns Colitis. 2014;8:1179-1207.
22. Dignass A, Lindsay JO, Sturm A, et al. Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management. J Crohns Colitis. 2012;6:991-1030.
23. Dignass A, Van Assche G, Lindsay JO, et al. The second European evidence-based consensus on the diagnosis and management of crohn's disease: current management. J Crohns Colitis. 2010;4:28-62.
24. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014;8:443-468.
25. Marks DJ, Miyagi K, Rahman FZ, Novelli M, Bloom SL, Segal AW. Inflammatory bowel disease in CGD reproduces the clinicopathological features of Crohn's disease. Am J Gastroenterol. 2009;104:117-124.
26. Jones LB, McGrogan P, Flood TJ, et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol. 2008;152:211-218.
27. Seger RA. Modern management of chronic granulomatous disease. Br J Haematol. 2008;140:255-266.
28. Marciano BE, Rosenzweig SD, Kleiner DE. Gastrointestinal involvement in chronic granulomatous disease. Pediatrics. 2004;114:462-468.
29. Holland SM. Chronic granulomatous disease. Hematol Oncol Clin North Am. 2013;27:89-99.
30. Uzel G, Orange JS, Poliak N, Marciano BE, Heller T, Holland SM. Complications of tumor necrosis factor-a blockade in chronic granulomatous disease-related colitis. Clin Infect Dis. 2010;51:1429-1434.
31. Gabrion A, Hmitou I, Moshous D, et al. Mammalian target of rapamycin inhibition counterbalances the inflammatory status of immune cells in patients with chronic granulomatous disease. J Allergy Clin Immunol. 2017;139:e6.